Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2023-11-10 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for PharmAbcine. It details specific amendments (정정신고) to a previous filing, including changes to third-party allocation, payment dates, and share issuance details. This type of regulatory filing in the Korean market, which reports on capital structure changes and share issuance, falls under the 'Share Issue/Capital Change' category.
2023-11-10 Korean
불성실공시법인지정(공시불이행 1건,공시번복 1건)
Regulatory Filings Classification · 100% confidence The document is an official regulatory announcement from the Korea Exchange (KOSDAQ) regarding the designation of 'PharmAbcine' as an unfaithful disclosure corporation due to disclosure violations (non-compliance and reversal). This falls under regulatory actions and compliance notifications, which are best categorized as Regulatory Filings (RNS) as it does not fit into specific categories like M&A, financial reports, or director dealings.
2023-11-02 Korean
주권매매거래정지(불성실공시법인 지정)
Delisting Announcement Classification · 100% confidence The document is a short, official notice regarding the suspension of stock trading for a specific company (PharmAbcine) due to being designated as an unfaithful disclosure corporation. It cites specific exchange regulations and provides the duration of the suspension. Since it is a regulatory announcement regarding trading status and does not fit into specific categories like M&A or share issuance, it falls under the general regulatory filing category.
2023-11-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity's shareholding in a listed company crosses a specific threshold (typically 5%). The document details the reporting entity (Ucon Partners Co., Ltd.), the target company (PharmAbcine), the number of shares held, the change in ownership, and the reason for the change (forced sale due to collateral ratio). This falls under the 'Major Shareholding Notification' category.
2023-10-30 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a Korean company (PharmAbcine) announcing a change in its largest shareholder (maximum shareholder). It details the before and after ownership stakes, the date of change, and the reason for the change. This type of disclosure regarding significant changes in shareholding structure and control is classified as a Major Shareholding Notification (MRQ) in the provided schema.
2023-10-30 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It specifically details a 'Decision on Paid-in Capital Increase' (유상증자결정), which involves the issuance of new shares to a third party. This falls under the category of share issuance and capital changes.
2023-10-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.